First vascularized model of stem cell islet cells [caption id="attachment_11877" align="aligncenter" width="1024"] Engineered vasculature induces functional maturation of pluripotent stem cell-derived islet organoidsResearchers have devised the right conditions to grow vascularized stem cell islets. The image shows vasculature (red) tightly wrapped around insulin-producing cells (green) in the islets (blue). ©…..
TreeFrog Therapeutics secures €30 million from EIB TreeFrog Therapeutics, a French biotech specializing in cell therapy, has secured a €30 million financing from the European Investment Bank (EIB). The financing will support the advancement of their lead cell therapy program in Parkinson’s Disease to the clinic. This cell therapy has…..
CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing of its stem cell-based therapy First clinical batches of ProtheraCytes® are planned for 2026 CellProthera, a French regenerative cell therapy developer specializing in ischemic diseases, has chosen CELLforCURE by SEQENS, as its contract development and manufacturing organization (CDMO) partner for its…..
CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies CRISPR Therapeutics, a Swiss biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Sirius Therapeutics, a sino-american clinical stage biotech company developing innovative small interfering RNA (siRNA) therapies for global markets, have concluded a…..
Why are patients with mitochondrial disease more susceptible to infections? The cell at the top right is dying through caspase-11 dependent pyroptosis, the mechanism West and colleagues identified in this paper. It's mitochondria are gone and the nucleus also condensed. ©The Jackson Laboratory Patients with rare mitochondrial diseases already face a…..
GNT0004 product confirms its clinical efficacy with stabilization of motor functions in patients treated at the effective dose for up to 2 years Genethon has unveiled the 2-year follow-up data from its GNT0004 gene therapy clinical trial for Duchenne Muscular Dystrophy (GNT-016-MDYF) at the annual meeting of the American Society…..
Launch of UMBRELLA study to personnalise post-treatment follow-up for cancer patients On May 19, 2025, Gustave Roussy announced the launch of UMBRELLA, a ground-breaking phase III clinical trial that could profoundly transform how cancer patients are monitored after curative treatment. The objective is to personalise post-treatment follow-up based on the…..
8.3 million euros for doctoral programme in regenerative medicine and ATMP Marie Jönsson, grant manager Stem Cell Center and Mattias Magnusson, director of RAMP-UP at the Lund Research School in Stem Cell Biology and group leader at the Stem Cell Center. ©Alexis Bento Luis Lund University in Sweden has been…..